Pimobendan in preclinical Doberman DCM: delaying CHF or sudden death — LIKELY

In Doberman Pinschers with preclinical (occult) dilated cardiomyopathy, does pimobendan vs placebo prolong the time to congestive heart failure or sudden death?

Shelf #202 · gate-verified and approved by the developer

LIKELY: Pimobendan prolongs the time to congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy. In PROTECT, a randomized, blinded, placebo-controlled, parallel group multicenter study of 76 Dobermans, the median time to the composite primary endpoint was 718 days on pimobendan vs 441 days on placebo (log-rank P = 0.0088), and median survival time was 623 vs 466 days (log-rank P = .034). The stamp stops at LIKELY because the trial is small (76 dogs) and the proportion of dogs reaching the primary endpoint was not significantly different between groups (P = .1) — the benefit rests on the time-to-event analyses. This pack is Tier C because its claim includes sudden death and survival. Drafted Nov 10, 2026 (VetMed build, topic #202); all figures from abstracts fetched and verified at drafting.

PROTECT (Summerfield 2012): pimobendan extended median time to CHF or sudden death from 441 to 718 days in Dobermans with preclinical DCM

Randomized, blinded, placebo-controlled, parallel group multicenter study (PROTECT)

Who: Dogs: 76 client-owned Doberman Pinschers with preclinical dilated cardiomyopathy, recruited at 10 centers in the UK and North America; allocated in a 1:1 ratio to pimobendan (Vetmedin capsules) or visually identical placebo.

Result: The proportion of dogs reaching the primary endpoint was not significantly different between groups (P = .1). The median time to the primary endpoint (onset of congestive heart failure or sudden death) was significantly longer in the pimobendan group (718 days, IQR 441-1152 days) versus the placebo group (441 days, IQR 151-641 days) (log-rank P = 0.0088). The median survival time was significantly longer in the pimobendan group (623 days, IQR 491-1531 days) versus the placebo group (466 days, IQR 236-710 days) (log-rank P = .034).

Watch out: Only 76 dogs, and the simple proportion reaching the endpoint did not differ significantly (P = .1) — the claim rests on time-to-event analyses. The population is one breed with preclinical DCM; the result does not automatically transfer to other breeds or to dogs already in heart failure.

Summerfield NJ, Boswood A, O'Grady MR et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). J Vet Intern Med. 2012;26(6):1337-1349. PMID: 23078651. Registry ID: none in the record. MeSH: Animals · Cardiotonic Agents · Death, Sudden · Dog Diseases · Dogs · Female · Heart Failure · Kaplan-Meier Estimate · Male · Pyridazines

Synthesis: a single small blinded placebo-controlled trial, positive on time-to-event, carries this shelf

Synthesis

Who: Synthesis of the card above: PROTECT (Summerfield 2012), the single trial on this shelf — a randomized, blinded, placebo-controlled, parallel group multicenter study of 76 Doberman Pinschers.

Result: This shelf rests on one trial, stated on its face. PROTECT was blinded and placebo-controlled with a hard composite primary endpoint (congestive heart failure onset or sudden death), and both the time to that endpoint (median 718 vs 441 days) and median survival time (623 vs 466 days) significantly favoured pimobendan. Its size (76 dogs) and the non-significant difference in the proportion reaching the endpoint keep the stamp at LIKELY rather than PROBABLE under the VetMed single-trial exception. The sudden-death and survival components make the pack Tier C.

Watch out: No second trial in preclinical Doberman DCM confirms this result, and sudden death in Dobermans also occurs from arrhythmia in dogs without the echocardiographic phenotype PROTECT enrolled — the shelf does not cover that group.

Synthesis of Summerfield NJ et al. PMID: 23078651. Registry ID as on the individual card.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.